Medical Supply Chain Resiliency Act
Official title: A bill to authorize the President to enter into trade agreements for the reciprocal elimination of duties or other import restrictions with respect to medical … Show full official titleShow less
Official title: A bill to authorize the President to enter into trade agreements for the reciprocal elimination of duties or other import restrictions with respect to medical goods to contribute to the national security and public health of the United States, and for other purposes.
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Read twice and referred to the Committee on Finance.
Medical Supply Chain Resiliency Act
This bill authorizes actions to facilitate trade in medical goods (i.e., medical devices, pharmaceutical goods, or inputs for such devices or goods).
Specifically, the bill authorizes the President to (1) negotiate, enter into, and enforce a trusted trade partner agreement with a country or countries with respect to medical goods; and (2) proclaim a modification of any existing duty, a continuance of existing duty-free or excise treatment, or additional duties to carry out the trade agreement. These actions may only be taken if the President determines, based on specified considerations, that the reciprocal elimination of existing duties or other import restrictions with respect to medical goods would contribute to U.S. national security and public health.
A trusted trade partner agreement may include certain provisions, such as those to (1) reduce or eliminate duties, quotas, or other trade barriers; (2) diversify and expand supplier networks to secure a reliable supply of medical goods; and (3) harmonize regulatory procedures.
Not later than 60 days before initiating negotiations with a trusted trade partner, the President must submit written notice to Congress. The bill requires congressional consultation and review of these trade agreements. A trade agreement shall not take effect if, during the required review period, Congress enacts a joint resolution of disapproval.
The Office of the U.S. Trade Representative must monitor compliance by a trusted trade partner with the trade agreement's commitments and obligations. Further, the President may take certain actions in response to a failure to comply.
- Introduced in Senate Formatted Text PDF Formatted XML
- FEDERAL HALL POLICY ADVISORS, LLC
- AKIN GUMP STRAUSS HAUER & FELD
- VIZIENT, INC.
- UPS (UNITED PARCEL SERVICE)
- CHAMBER OF COMMERCE OF THE U.S.A.
- GOLDSTEIN POLICY SOLUTIONS LLC
Bodies those filers lobbied
- HOUSE OF REPRESENTATIVES
- SENATE
- Health & Human Services, Dept of (HHS)
- U.S. Trade Representative (USTR)
- Centers For Medicare and Medicaid Services (CMS)
- Commerce, Dept of (DOC)
- Office of Management & Budget (OMB)
- White House Office
Cite this page
U.S. Congress. (2026). S. 998: Medical Supply Chain Resiliency Act. 119th Congress. Open America. https://openamerica.io/bill/119-S-998/
"S. 998: Medical Supply Chain Resiliency Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-S-998/.
S. 998, 119th Cong. (2026), https://openamerica.io/bill/119-S-998/.
[S. 998: Medical Supply Chain Resiliency Act](https://openamerica.io/bill/119-S-998/)